0.40
0.00%
+0.00
After Hours:
.4095
0.0095
+2.37%
Qualigen Therapeutics Inc stock is currently priced at $0.40, with a 24-hour trading volume of 79,811.
It has seen a +0.00% increased in the last 24 hours and a -14.89% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.3925 pivot point. If it approaches the $0.4075 resistance level, significant changes may occur.
Qualigen Therapeutics Inc Stock (QLGN) Financials Data
Qualigen Therapeutics Inc (QLGN) Revenue 2022
QLGN reported a revenue (TTM) of $4.79 million for the quarter ending June 30, 2022, a +0.62% rise year-over-year.
Qualigen Therapeutics Inc (QLGN) Net Income 2023
QLGN net income (TTM) was -$17.34 million for the quarter ending September 30, 2023, a -5.17% decrease year-over-year.
Qualigen Therapeutics Inc (QLGN) Cash Flow 2023
QLGN recorded a free cash flow (TTM) of -$7.19 million for the quarter ending September 30, 2023, a +48.43% increase year-over-year.
Qualigen Therapeutics Inc (QLGN) Earnings per Share 2023
QLGN earnings per share (TTM) was -$3.74 for the quarter ending September 30, 2023, a +18.87% growth year-over-year.
Qualigen Therapeutics Inc Stock (QLGN) Latest News
Why Richardson Electronics Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket
Benzinga
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
GlobeNewswire Inc.
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
GlobeNewswire Inc.
Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer
GlobeNewswire Inc.
About Qualigen Therapeutics Inc
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Cap:
|
Volume (24h):